IAS Rio 2005 International AIDS Society IAS Rio 2005 Programme-at-a-Glance
Delegate Connector Webcast FAQ Media Centre Site map Contact us

New antiretroviral targets and compounds, mechanisms of drug resistance WePp01
Type: Poster Presentations
Venue: Poster presentation area
Time: 12:30 - 13:45
Chairperson: Ricardo Sobhie Diaz, Brazil

    Presentations in this session:

12:35
WePp0102   
Abstract
The L74V mutation in HIV-1 RT impairs unblocking of ZDV-terminated DNA primers and reduces synthesis of viral DNA in real-time PCR
Frankel F.1, Marchand B.1, Götte M.1, Wainberg M.A.1
1McGill University AIDS Centre, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada
12:40
WePp0103   
Abstract
Binding energetics analysis shows a unique response of tipranavir to HIV-1 protease mutations associated with drug resistance
Muzammil S.1, Kang L.-W.2, Armstrong A.A.2, Jakalian A.3, Bonneau P.R.3, Schmelmer V.4, Amzel L.M.2, Freire E.1
1Department of Biology, Johns Hopkins University, Baltimore, MD, United States of America, 2Department of Biophysics and Biophysical Chemistry, The Johns Hopkins University School of Medicine, Baltimore, MD, United States of America, 3Boehringer Ingelheim (Canada) Ltd. Research & Development, Laval, Québec, Canada, 4Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT, United States of America
12:45
WePp0104   
Abstract
Multivalent compounds functionalized with the carbohydrate headgroups of immune cell-surface GSLs as inhibitors of HIV-1 infection.
Rosa Borges A.1, Puri A.2, Krebs F.C.3, Wigdahl B.3, Blumenthal R.2, Rawat S.S.2, Johnson B.T.2, Schengrund C.-L.1
1Penn State University, College of Medicine, Hershey, Pennsylvania, United States of America, 2Center for Cancer Research, National Cancer Institute, Frederick, Maryland, United States of America, 3Drexel University, College of Medicine, Philadelphia, Pennsylvania, United States of America
12:50
WePp0105   
Abstract
Crystallographic study with BILR 355 BS, a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) with a broad anti HIV-1 profile
Coulombe R.1, Fink D.1, Landry S.1, Lessard I.A.D.1, McCollum R.1, Naud J.1, O'Meara J.1, Simoneau B.1, Yoakim C.1, Bonneau P.R.1
1Boehringer Ingelheim (Canada) Ltd, Laval, Canada
12:55
WePp0106   
Abstract
Novel compounds that inhibit HIV replication by acting through inhibition of HIV rev function
Rekosh D.1, Ptak R.2, Hammarskjold M.-L.1
1University of Virginia, Department of Microbiology, Charlottesville, VA, United States of America, 2Southern Research Institue, Department of Infectious Disease Research, Frederick, MD, United States of America


    Back to the Programme-at-a-Glance

Copyright Notice © IAS Disclaimer